Key facts
- EndoGene.Bio’s last known valuation is $1.1M (Feb 2022).
- It has raised $1.7M; the latest was Early Stage VC in Feb 2025.
- Notable investors include Bpifrance, Entrepreneurs First, Frontline Ventures, Chemostart, Genopole.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for EndoGene.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for EndoGene.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EndoGene.Bio
Developer of a biotechnology platform intended to use precision medicine to transform how endometriosis is diagnosed and treated. The company's platform helps to accelerate the diagnosis of endometriosis from months to weeks through a non-invasive endometriosis diagnostic test for improved diagnostics, patient stratification, and drug development using menstrual blood, enabling medical professionals to easily prepare tests based on proprietary epigenetic biomarkers in menstrual blood.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 14
- Website
- endogene.bio/
- Ownership
- Privately Held (backing)
EndoGene.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoGene.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoGene.Bio in its N-PORT filings yet. We sweep new filings monthly.